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Androgen depletion is a key strategy for treating human prostate cancer, but the presence 
of  hormone-independent  cells  escaping  treatment  remains  a  major  therapeutic  challenge. 
Here, we identify a minor subset of stem-like human prostate tumour-initiating cells (TICs) 
that do not express prostate cancer markers, such as androgen receptor or prostate specific 
antigen. These TICs possess stem cell characteristics and multipotency as demonstrated by 
in vitro sphere-formation and in vivo tumour-initiation, respectively. The cells represent an 
undifferentiated subtype of basal cells and can be purified from prostate tumours based on 
coexpression of the human pluripotent stem cell marker TRA-1-60 with CD151 and CD166. Such 
triple-marker-positive TICs recapitulate the original parent tumour heterogeneity in serial xeno-
transplantations indicating a tumour cell hierarchy in human prostate cancer development. 
These  TICs  exhibit  increased  nuclear  factor-κB  activity.  These  findings  are  important  in 
understanding the molecular basis of human prostate cancer. 
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P
rostate cancer is a pressing public concern, as it has become the 
most common form of cancer in men in the Western world. 
Although androgen deprivation is a key therapeutic strategy 
in human prostate cancer, a small number of prostate cancer cells 
can thrive after anti-androgen treatment and become lethal even 
with castrate levels of testosterone1,2. This highlights the presence of 
androgen independent cells with tumour-regenerating capacity and 
the need for targeting them. It is well known that the normal pros-
tate can undergo repeated cycles of castration-dependent regression 
and hormone-induced regrowth when supported by populations of 
putative prostate stem cells3,4. In normal development of the pros-
tate gland, a subset of androgen-independent basal and/or interme-
diary cells can function as multipotent progenitors that give rise to 
androgen-dependent differentiated luminal cells5,6.
Human prostate cancers may also contain rare and distinct stem-
like cells responsible for tumour formation similar to those found 
in other cancers7–11. Multiple cell types in the prostate gland have 
also been considered to be potential cell(s) of origin for tumour 
development12–15.  For  example,  a  subset  of  castration-resistant 
postmitotic luminal cells was demonstrated to acquire prolifera-
tive capacity causing an expansion of luminal cells associated with 
mouse prostate tumours in a pten tumour suppressor deleted back-
ground14. These results were in agreement with a previously sug-
gested dedifferentiation model of cancer cell origin16. However, in 
other studies basal epithelial stem-like cells were also shown to be 
efficient targets for tumour-initiation in murine prostate cancer13. 
Although these data suggest that murine prostate cancer can arise 
from multiple tumour cell types, the identification of specific mark-
ers  for  prospective  isolation  of  precisely  tumour-initiating  cells 
(TICs) has remained an important aim in the field of human pros-
tate cancer research.
Normal and cancer stem cells were believed to express a shared set of 
markers17. However, because of their heterogeneous expression within 
normal and tumour tissues, many putative stem cell markers, such as 
CD44, CD133 and their isoforms, identify multiple cell types including 
sub-populations of stromal cells and interstitial cells such as immuno-
stimulatory  cells2,16,18,19.  Moreover,  in  vitro  cell  culture  conditions,   
in vivo tissue differentiation or exposure to cytokines affect expression 
of these markers and also result in considerable overlap of signalling 
pathways between cells that are positive and negative for these mark-
ers20–24.  Therefore,  identification  of  unique  markers  and  signalling 
pathways in TICs has become an important goal for understanding the 
molecular basis of human prostate cancer and for developing precise 
therapeutic strategies in patients.
In this study, we isolated TICs with stem cell-like properties from 
human prostate tumours. These cells are androgen receptor (AR)-
negative, express TRA-1-60 and exhibit active nuclear factor κB 
(NF-κB) signalling. Our findings suggest that the functional NF-κB 
pathway may be important in maintaining the conventional therapy 
resistant stem-like TICs in human prostate cancer.
Results
Stem cell-like cells in human prostate tumours. We investigated the 
human prostate TICs using the CWR22 orthotopic (OT, injection 
into prostate) tumour xenograft system that offers a reproducible 
in vivo source for providing sufficient amounts of human prostate 
tumour  cells  from  a  native  microenvironment  over  successive 
transplantations25. We reasoned here that a sub-population of self-
renewing stem-like prostate cancer cells is responsible for sustaining 
tumour growth through sequential transplantations in a manner 
comparable to that observed in many other human cancers18. We 
first investigated sphere-formation ability of the tumour cells as 
a surrogate in vitro assay for their self-renewal ability and for the 
retrospective identification of stem-like tumour cells26. We observed 
that dissociated tumour cells formed spheres, which we henceforth 
will refer to as ‘primary spheres’.
However,  the  sphere  formation  efficiency  was  very  low  (1–2 
spheres/2,500–5,000 total tumour cells) as determined by limiting 
dilution assays (Fig. 1a). A minor subset of human patient primary 
prostate tumour cells also had sphere-forming ability albeit with even 
lower efficiency (about tenfold less). We observed a gradual increase 
in the total number of primary spheres formed over time for a given 
number of total tumour cells (Fig. 1b), sphere growth as determined 
by the increase in number of cells per sphere (Fig. 1c) and sphere-
forming ability of serially passaged sphere cells (about 5- and 25-fold 
higher in secondary and tertiary sphere formation assays, respec-
tively; Fig. 1d). These data demonstrate differential sphere-forming 
abilities among various cell types in the tumour and rule out sim-
ple cell aggregation as a primary mechanism of sphere formation.   
Quantitative analysis of tumour-initiation efficiency through limit-
ing dilution experiments revealed that tumour-initiation with pri-
mary sphere-cells was at least 100-times more efficient than with   
the total tumour cells (Fig. 1e). Moreover, tumour initiation at OT 
versus sub-cutaneous (SC)-sites was about ten-times more efficient. 
Unless otherwise stated, we used OT-tumour-initiation assays in all 
further experiments.
The  stem-like  TICs  do  not  express  androgen  receptor  and   
prostate-specific antigen. The spheres express distinct characteris-
tics and are multipotent as the sphere-cell-derived tumours (sphere 
tumours) reconstituted histopathological features and immunophe-
notypes of the original OT-human prostate CWR22 tumour (parent   
tumour) and closely mimicked the features of freshly obtained patient 
prostate tumour specimens (primary tumours; Fig. 1f–h; Supplemen-
tary Fig. S1a–d). Thus, these stem-like sphere cells do not express key 
markers of prostate cancer, including AR, prostate specific antigen 
(PSA),  NKX3.1  (androgen/AR-regulated  transcriptional  coactiva-
tor) and cytokeratin-18 (CK18, differentiated luminal cell enriched 
marker). In contrast, cancer stem cell and cell-proliferation-associ-
ated markers MET receptor kinase, Musashi-1, inhibitor of differenti-
ation 1, phospho-histone 3 and Ki67 are selectively enriched in these 
spheres relative to tumours. We also found that the AR-/PSA-negative 
stem-like sphere cells are of basal epithelial-like cell type based on the 
expression of E-cadherin, cytokeratin-5 (CK5) and SOX9 and lack of 
expression of markers of myoepithelial cells (smooth muscle actin), 
mesenchymal cells (vimentin) and neuroendocrine cells (synapto-
physin). However, these sphere cells also lack detectable expression 
of basal cell enriched, p63 and its polarity associated, zonula occlu-
dens-1 (ZO-1). Thus, these sphere-forming TICs represent a distinct 
cancer stem-like cell compartment in the human prostate tumour.
Human prostate TICs express novel pluripotent cell markers. By 
fluorescence-activated cell sorting (FACS), we investigated novel cell 
surface marker expression that could facilitate prospective isolation 
of the TICs in the human prostate CWR22 OT-tumours. First, we 
confirmed the expression of a set of markers known to associate with 
stem-like tumour cells in other epithelial cancers, including human 
prostate  tumours17,27.  They  included  epithelial  cellular  adhesion 
molecule (EpCAM), hyaluronic acid receptor (CD44) and integrins 
(α2-integrin, α6-integrin and β4-integrin; Fig. 2a). Prostate tumour 
cells  expressing  these  markers  displayed  increased  sphere-forma-
tion capacity as compared with unsorted total tumour cells or cells 
expressing β4-integrin (Fig. 2b). Except for CD44, the percentage of 
cells expressing these markers (EpCAM, α2-integrin for example) 
was consistently enriched over sequential passages of sphere cells. The 
above markers are associated with many different cell types including 
stromal and/or interstitial cells in the prostate and in other organs. 
Therefore, to facilitate precise identification of stem-like TICs, we 
investigated novel markers such as the tumour rejection antigen, TRA-
1-60, a cell surface epitope of human embryonic, embryonal germline 
and teratocarcinoma stem cells28. Sphere-forming cells and a subset of 
tumour cells express TRA-1-60, related pluripotent stem cell markers   ARTICLE     
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Figure 1 | A subset of human prostate TICs exhibits sphere-forming potential and multipotency. unless stated otherwise, human prostate CWR22 
oT-tumours were used. (a) Phase contrast images of primary sphere formation by the total tumour cells. Scale bar, 100 µm. (b) Time course of primary 
sphere formation (sphere number per 8×105 total tumour cells plated, n = 4). (c) Time course of primary sphere growth (average number of cells per 
primary sphere, n = 4). (d) Efficiency of sequential derivation of primary (blue circle), secondary (green square) and tertiary spheres (black triangle) 
determined as a function of equal numbers of starting cells from total tumour, primary spheres and secondary spheres, respectively; n = 4. (e) Limiting 
dilution experiments determining tumour-initiation efficiency (% tumour induction) at the orthotopic (blue, tumour cells; red, primary sphere cells)  
and subcutaneous (black, tumour cells; green, primary sphere cells) sites. Data represents the 4-week end-point results following transplantation. 
mean ± s.d. (n = 4). (f, g) CWR22 oT-tumour (parent tumour), the tumour cell-derived primary spheres (spheres), the sphere-derived oT-tumour  
(sphere tumour) and human patient primary prostate tumour (primary tumour) were used for comparative immunohistochemistry (IHC). Scale bar, 50 µm.  
(f) Comparative IHC for expression of differentiated prostate cell markers (AR, PSA and mET) in primary spheres versus tumours. (g) Comparative 
IHC for expression of markers for epithelial cells (E-cadherin) versus differentiated cells in the tumour, namely neuroendocrine cells (synaptophysin), 
myoepithelial cells (smooth muscle actin, SmA), and mesenchymal cells (vimentin). (h) Western blots of whole cell extracts of the parent tumour, 
primary spheres and sphere tumour analyzing the expression of markers for prostate basal cell (CK5), luminal cell (AR, PSA, NKX3.1, CK8 and CK18), 
primary prostate cancer cell (mET, αB-crystallin and maspin), putative stem cell (musashi-1, mSH-1), basal epithelial stem cell (SoX9), cell polarity/
differentiation (Zo-1) and loading control (glyceraldehyde 3-phosphate dehydrogenase, GAPDH).ARTICLE
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such as TRA-1-81 and stage-specific embryonic antigens such as 
SSEA1, SSEA4 for example (Fig. 2a, c–f; Supplementary Fig. S2). 
TRA-1-60 or TRA-1-81-positive tumour cells formed spheres more   
efficiently than cells positive for other known markers (Fig. 2b,g), and 
the TRA-1-60-positive tumour cells were moderately more efficient 
in tumour induction than the primary sphere cells (Fig. 3a).
Mouse OT xenografts of human prostate tumour tissue contain 
a  mixed  population  of  cells  expressing  both  human  and  mouse 
antigens. Therefore, we verified that expression of human-specific 
epitopes, such as major histocompatibility complex (MHC) HLA-
Class I ABC, but not mouse-specific antigen MHC Class I H-2Kd and 
stem cell antigen-1 (Sca-1), in the tumour cells was correlated with 
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Figure 2 | Prospective isolation and characterization of human prostate TICs. (a) Percent marker expression in parent tumours (red) or the sequentially 
derived primary (green) and secondary (blue) spheres. mean ± s.d. (n = 10). (b) Primary sphere formation is affected by the markers expressed in tumour 
cells (primary spheres/5,000 tumour cells). mean ± s.d. (n = 10). (c, d) Percent coexpression of TRA-1-60 and (c) human-specific-PSmA or -EpCAm or 
(d) mouse-specific mHC Class I H-2KD or -Sca-1 in tumour cells. mean ± s.d. (n = 4). (e) Immunofluorescence labelling of TRA-1-60, CD151 and CD166 in 
primary spheres and 4′-6-diamidino-2-phenylindole (DAPI) represents counterstain. Scale bar, 50 µm. (f) Percent combinatorial expression of the triple-
markers in tumour cells. mean ± s.d. (n = 8). (g) marker-specific primary sphere-formation efficiency (determined as above in b). mean ± s.d. (n = 5).ARTICLE     
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their sphere-formation (Fig. 2a,b) and tumour initiation (Table 1)   
abilities.  Moreover,  the  TRA-1-60-positive  cells  also  express  the 
human-specific-EpCAM,  as  well  as  -PSMA  epitopes  (Fig.  2c), 
whereas the tumour cells double positive for expression of TRA-1-
60 and mouse specific Sca-1 or H-2Kd were not found (Fig. 2d). This 
indicates that the sphere-forming and tumour-initiating TRA-1-60-
positive cells represent epithelial cells of human prostate cell origin.
Next, we investigated the expression of additional markers such 
as CD166 and CD151, which are known to associate with colon 
  epithelial cancer stem cells29 and other stem-like cells in tumour 
stroma,  respectively,  and  during  prostate  cancer  progression30  
(Supplementary Fig. S2). Tumour cells expressing CD151 or CD166 
exhibited greater efficiency in sphere formation than any of the 
above  tested  markers  (Fig.  2a,b)  and  immunofluorescence  veri-
fied their expression in spheres, akin to that of TRA-1-60 (Fig. 2e).   
Sphere-forming  and  tumour-initiation  abilities  were  signifi-
cantly diminished in cells sorting negative for expression of TRA- 
1-60, CD151 or CD166 (Figs 2g, 3b,c; Table 1). We also tested for   
120
α2-Int
EpCAM Triple
pos.
TRA-1–60
Sca-1
250
200
150
100
50
0
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Triple
neg. CD44
TRA-1–60
2.5
18
16
14
12
10
8
6
4
2
0
%
 
M
a
r
k
e
r
 
e
x
p
r
e
s
s
i
o
n
2
1.5
1
0.5
0
Control
Passage 1
Passage 4
Passage 5
Passage 6
S
p
h
e
r
e
s
T
u
m
o
u
r
%
 
T
r
i
p
l
e
 
p
o
s
i
t
i
v
e
s
C
e
l
l
 
c
y
c
l
e
 
p
h
a
s
e
s
 
(
%
)
CD166 CD151 Unsorted
80
60
40
20
0
kDa
95
135
42
52
34
AR
ZO-1
MSH-1
CK18
GAPDH
Tra-1–60
CD151
CD166
Triple pos.
Triple
β4-Int
100
80
60
40
20
0
Pri Sph cells/SC
Pri Sph cells/OT
TRA-1–60+ cells/SC
TRA-1–60+ cells/OT
Triple positive cells/SC
Triple positive cells/OT
Unsorted
TRA-1–60
CD151
CD166
Triple pos.
Triple neg.
Unsorted
Unsorted
TRA-1–60
TRA-1–60
CD151
CD151
CD166
CD166
Triple pos.
Triple positive
Triple neg.
Sca-1
%
 
T
u
m
o
u
r
 
i
n
d
u
c
t
i
o
n
Figure 3 | In vivo tumour-initiation by purified human prostate TICs. (a) Limiting dilution experiments for determining percent tumour-initiation by 
equal numbers of sphere cells, TRA-1-60-positive cells or triple positives transplanted at oT or SC sites. Blue, 10,000 cells; green, 1,000 cells and 
red, 200 cells. Data represents the 4-week end-point results following transplantation. (b–h) unless otherwise stated, 5,000 marker-positive or total 
tumour (unsorted control) cells were used per transplantation. (b) Representative SC tumour growth at 5 weeks following transplantation. unsorted 
represents a control tumour-derived from transplantation of 2×106 total tumour cells. (c) Tumour-initiation efficiency (represented as tumour volume) 
of the marker-positive cells at 5 weeks following transplantation. (d) upper panel: Dark field images of primary spheres formed by marker-positive cells. 
Lower panel: hematoxylin and eosin staining of tumours derived from different marker-positive tumour cells. Scale bar, 100 µm. (e) Relative levels of 
G1 (yellow), G2 (blue) and S (red) phases of cell cycle in the different marker-positive tumour cells. unsorted represents total tumour cells. (f) Percent 
triple-marker expression in sequentially passaged oT-tumours that were initially derived from the triple-marker-positive tumour cells. Percentage triple-
marker-positive cells in the parent tumour form the control. (g) maintenance of triple-marker-positive cells in the secondary passaged tumours derived 
from indicated marker-specific primary tumour cells. unsorted is as described in (b). orange-triple-marker-positive cells and purple-triple-marker-
negative cells. (h) Immunoblot analysis of whole cell extracts of the tumours derived from marker-positive tumour cells. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) represents the loading control. mean ± s.d., n≥3.ARTICLE
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combinatorial expression of the above three markers (Supplemen-
tary Figs S3 and S4), and identified a minor triple-marker-positive 
subset  (TRA-1-60 + CD151 + CD166 +   cells)  among  various  sub- 
populations of cells expressing other possible marker combinations   
(Fig. 2f). The triple-marker-positive cells had considerably higher 
sphere-forming ability than the single or double positives and tri-
ple  negatives  (Fig.  2g).  The  sphere-forming  ability  could  not  be 
enhanced even after combining all three individual subsets of cells 
exclusively expressing one of the above three markers suggesting 
that coexpression of the three markers reflects a hierarchical organi-
zation of sphere formation propensity in the prostate tumour cells.
Limiting  dilution  studies  revealed  that  prospectively  purified   
triple-marker-positive cells reproducibly formed tumours at OT and 
SC locations with at least fivefold more efficiency than those formed 
with the TRA-1-60-positive cells (Fig. 3a). When compared with 
an equal number of cells-positive for gross expression of any of the 
above markers, the triple-marker-positive cells induced increased 
tumour growth (Fig. 3b,c) and enhanced onset of tumour-initiation 
(Table 1). Similar to the data on sphere formation, cells exclusively 
positive for any one or two of the three markers (but negative for the 
remaining marker(s)), unsorted single cells derived from tumour, 
human β4-integrin-positive cells or mouse-specific MHC Class I 
Table 1 | Tumour initiation by sphere cells and purified tumour cells.
Cell number Cell phenotype SC transplants OT transplants Tumour onset time (weeks)
Human-versus mouse cells
  1,000,000 Total tumour cells 2/2 2/2 4–6
  200,000 (mHC) HLA-class I ABC +  
tumour cells
2/2 2/2 4–6
  200,000 (mHC) HLA-class I ABC −  
tumour cells
0/2 0/2 NA
  200,000 mHC class I H-2Kd +  
tumour cells
0/2 0/2 NA
Tumour versus sphere cells
  5,000 Total tumour cells 0/9 0/2 NA
  5,000 Primary Sphere cells 4/4 3/3 4–6
  5,000 Secondary sphere cells 4/4 3/3 4–6
  5,000 Tertiary sphere cells 4/4 2/2 4–6
Marker specificity
  5,000 EpCAm +  tumour cells 5/5 3/3 4–6
  5,000 CD44 +  tumour cells 5/5 3/3 4–6
  5,000 α2-Integrin +  tumour cells 5/5 3/3 4–6
  5,000 β4-Integrin +  tumour cells 0/5 0/2 NA
  5,000 Sca1 +  tumour cells 0/4 0/4 NA
  5,000 Human PrEC (non-
tumourigenic) cells
0/3 0/2 NA
  5,000 Human RWPE1 
(immortalized and 
untransformed) cells
0/3 0/2 NA
  5,000 TRA-1-60 +  tumour cells 10/11 4/4 4–6
  5,000 PSmA +  tumour cells 0/3 0/2 NA
  5,000 TRA-1-60 −  tumour cells 0/3 0/4 NA
  5,000 PSmA + /TRA-1-60 +  
tumour cells
3/3 2/2 4–6
  5,000 TRA-1-60 +  primary sphere 
cells
4/4 2/2 4–6
  5,000 TRA-1-60 +  secondary 
sphere cells
2/2 2/2 4–6
  5,000 TRA-1-60 +  tertiary sphere 
cells
2/2 2/2 4–6
Combinatorial marker expression
  5,000 CD 151 +  tumour cells 5/5 3/3 4–6
  5,000 CD 166 +  tumour cells 6/6 3/3 4–6
  5,000 Triple marker (TRA-1-
60 + CD151 + CD166) +  
tumour cells
5/5 6/6 2–3
  5,000 TRA-1-60 + /CD 
151 − /CD166 −  tumour cells
0/3 0/2 NA
  5,000 TRA-1-60 − /CD 
151 + /CD166 −  tumour cells
0/3 0/2 NA
  5,000 TRA-1-60 − /CD 
151 − /CD166 + tumour cells
0/3 0/2 NA
  5,000 TRA-1-60 − /CD 
151 − /CD166 − tumour cells
0/3 0/2 NA
  5,000 Triple-marker-negative 
tumour cells
0/3 0/3 NA
Abbreviation: NA, not applicable.ARTICLE     
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H-2Kd- and Sca-1-positive cells served as negative controls in the 
tumour-initiation experiments. Human prostate non-tumourigenic 
epithelial cells obtained from two independent sources (PrEC from 
Lonza and RWPE1 from American Type Culture Collection) also 
did not initiate tumour formation under these conditions (Table 1).
Interestingly,  tumours  derived  from  various  marker-positive 
tumour cells with different sphere-forming efficiencies or unfrac-
tionated  total  tumour  cells  (Fig.  3d)  displayed  comparable  his-
topathological features (Fig. 3d) with comparable levels of cell cycle 
phases (Fig. 3e). Tumour derived from triple-marker-positive cells 
could be serially passaged in vivo (at least six passages) without 
obvious changes in percentage of marker-positive cells (Fig. 3f). 
Tumours induced from single marker-positive cells gave rise to both 
marker-positive and -negative cells (Fig. 3g) and showed biochemi-
cal marker expression profiles (Fig. 3h) similar to those observed in 
parent tumours (Fig. 1h). These results also suggest that the triple-
marker-positive cells both self-renew and differentiate by recapitu-
lating a cellular hierarchy of the original parent tumour.
The triple-marker expression and the association with tumour-ini-
tiation were consistent in additional human prostate cancer cell line-
derived xenograft tumour models, namely, androgen-independent 
metastatic prostate cancer cell line-derived DU-145 (brain metasta-
sis), PC3 (bone metastasis) and VCaP (vertebral metastasis) xenograft 
tumours,  and  also  in  another  androgen-dependent  and  human 
patient-derived  primary  OT-xenograft  tumour  (PC-82;  Table  2;   
Supplementary Fig. S5). All the resulting tumours exhibited their 
expected  immunohistochemical  characteristics  (Fig.  4a)  such  as 
cytosolic localization of AR in androgen-insensitive DU-145 and PC3 
tumours,  or  nuclear  localization  in  androgen-sensitive  VCaP  and 
PC-82 tumours. All these tumours contained a set of triple-marker-
positive cells (Table 2). Tumours derived from triple-marker-positive 
DU-145 tumour cells were sequentially passaged in vivo over multiple 
transplantation cycles (Fig. 4b). The marker-positive cells from the 
DU-145 tumour recapitulated the original parent tumour heteroge-
neity by hierarchically differeniating in vivo into both marker-positive 
and -negative tumour cells. Marker expression and sphere-forming/
tumour-initiating abilities were also correlated in the DU-145 tumour 
cells, although the marker negative cells have considerably dimin-
ished sphere-forming and tumour-initiating abilities (Fig. 4c,d). We 
next verified the expression of each of these triple-markers in freshly 
resected human patient specimens from prostate tumour by immun-
ofluorescence (Fig. 4e) and FACS (Fig. 4f) or from other epithelial 
tumours of breast, colon and ovary by FACS (Fig. 4g). Cells positive 
for expression of the TRA-1-60 and triple-marker-positive cells were 
enriched in other epithelial tumour specimens when compared with 
the respective patient-matched normal tissues.
Global gene expression in stem-like human prostate TICs. To 
gain molecular insights into the potential mechanism(s) behind the 
functional correlation between cell surface markers expression and 
their sphere-/tumour-forming efficiency (S/TFE), we determined 
global expression patterns of both mRNAs and microRNAs (miR-
NAs) from the same marker-positive cells. We classified the result-
ing data into three sets based on their marker-specific functional 
S/TFEs: (a) high S/TFE set (representing the triple-marker-positive 
tumour cells that coexpress TRA-1-60, CD151 and CD166; n = 3), 
(b) moderate S/TFE set (representing tumour cells positive for gross 
expression of TRA-1-60, CD151 or CD166; n = 7) and (c) low S/TFE 
set (representing tumour cells positive for gross expression of α2-
integrin, EpCAM or CD44; n = 3). The above data sets were paired 
against the controls derived from unsorted matched tumour cells 
(n = 6) or cells positive for expression of β4-integrins.
Expression of a set of mRNAs was shared in all the S/TFE data 
sets (Fig. 5a). In contrast, only a few shared miRNAs were observed 
among all three S/TFE data sets (Supplementary Fig. S6a). But a 
relatively large list of miRNAs was common between moderate and 
high S/TFE data sets. Gene expression data analysis using DAVID31 
(http://david.abcc.ncifcrf.gov) and gene ontology revealed a striking 
enrichment in gene expression related to cell development, differ-
entiation and cell death (Fig. 5b). Importantly, an involvement of 
protein kinase C (PKC)/NF-κB signalling axis was evident in all the 
mRNA data sets (as exemplified by NFKBIA, LGALS1, CRYAB (αB-
crystallin), IFIH1, CGB5, CGB8, XM_938419, NRAP, PTPLAD2, 
TSHZ1; Fig. 5c–f) and the miRNA data sets (Supplementary Fig. 
S6b–e) in addition to those related to stem cell biology, embryonic 
development and oncogenesis.
Constitutive NF-κB signalling and function in the stem-like TICs. 
We  investigated  the  differences  between  the  TRA-1-60-positive 
spheres with tumour-initiating potential and tumours with regards 
to various signalling pathways mediated by canonical receptor tyro-
sine kinase, insulin, AKT, ERK and Wnt (for example, β-catenin 
expression). Except for a diminished level of insulin growth factor 
receptor 1β phosphorylation in the spheres (Fig. 6a; Supplementary 
Fig. S1a,b,d), there were no considerable differences in the activation 
of conventionally studied signalling pathway components. There-
fore, we reasoned from genome-wide expression data that consti-
tutively active PKC/NF-κB pathway may be functionally associated 
with the stem-like human prostate TICs. We verified that a classi-
cal PKC (PKC α) was specifically activated in the stem-like TICs 
by immunoblotting for PKC α protein phosphorylation (Fig. 6a).   
However, levels of other PKCs (pan-phosphorylated PKCβII and 
atypical PKCs, PKC ζ/λ) remained unaffected, whereas the PKD or 
PKCµ remained moderately lower in the sphere cells as compared 
with the tumour cells. Next, we confirmed the microarray data on 
downregulation of transcription of NFKBIA (Fig. 5c) with a specific 
decrease in its protein level, by including the other positive controls 
such as IGFBP7 and αB-crystallin (Figs 1h and 6a). There was also 
an increased accumulation of NF-κB p65 and its K310 acetylated 
form specifically nuclear localized in the spheres (Fig. 6b), implying 
a potential functional importance of sustained NF-κB signalling, as 
deacetylation of NF-κB p65 was previously shown to inhibit its tran-
scriptional activity and induce cellular apoptosis32. Furthermore, the 
sphere cells showed increased levels of a proinflammatory cytokine 
interleukin 6 (IL-6), the anti-apoptotic Bcl-2 family member human 
myeloid cell leukemia-1 (MCL-1) and additional regulators of epi-
thelial cell proliferation and apoptosis, such as 14-3-3σ (Fig. 6a,c).
We additionally exploited the in vitro secondary sphere-forma-
tion assay to investigate the functional effects of various signalling 
pathway inhibitors on the primary sphere-forming TICs. Adminis-
tration of MET inhibitor (PHA: PHA 665752) and NF-κB activation 
inhibitors (481407 compound, parthenolide and celastrol) inhibited 
Table 2 | Percent marker-positive cells in various human prostate tumours.
Human prostate tumours TRA-1-60 CD151 CD166 Triple positive
Du-145 tumour (brain metastasis) 0.8 17.9 34.3 0.4
PC3 tumour (bone metastasis) 0.1 27.0 40.0 0.1
VCaP tumour  
(vertebral metastasis)
0.5 16.3 9.5 0.3
PC-82 tumour (primary) 0.2 14.1 27.2 0.1ARTICLE
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Figure 4 | Triple-marker expression in other prostate tumours and patient specimens. (a) Comparative immunohistochemical characterization of 
Du-145, PC3, VCaP and PC-82 tumours. Scale bar, 50 µm. (b) Percent marker-positive cells maintained after sequential in vivo passages of Du-145 
tumours that were initially derived from the triple-marker-positive cells. Blue, passage1 and light blue, passage2. mean ± s.d. (n = 4). (c) In vitro primary 
sphere-formation and (d) In vivo tumour initiation. Prospectively isolated 2,500 marker-positive Du-145 tumour cells were used. Tumour size was 
determined as tumour volume. mean ± s.d. (n = 4). unsorted control represents single cells of tumour. (e) Immunofluorescence labelling of markers in 
fresh frozen human patient primary prostate tumour specimens, with 4′-6-diamidino-2-phenylindole (DAPI) counterstain. Scale bar, 100 µm. (f) Percent 
marker-positive cells in human patients’ prostate tumour specimens. mean ± s.d. (n = 6). (g) Percent marker-positive cells in a variety of epithelial tumour 
specimens from clinical patients. Red, tumour cells and green, patient-matched normal tissue cells. mean ± s.d. (n = 3). ARTICLE     
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secondary sphere formation in a dose-dependent manner (Fig. 6d). 
Similar to the activation inhibitors of NF-κB, other pharmacologi-
cal inhibitors of NF-κB (MG 132, functioning at the level of pro-
teasomes inhibition) and PKC (such as staurosporine), but not the 
IkBα phosphorylation inhibitor (BAY 11-7085, as expected from 
the lack of NFKBIA in the spheres) abrogated the secondary sphere-
formation ability (Fig. 6e). Inhibitors of phosphoinositide-3-kinase 
and  mTOR  (LY294002  and  rapamycin,  respectively),  hedgehog 
(cyclopamine), γ-secretase/Notch (DAPT) and MAP kinase kinases 
(MEK inhibitor: U0126) also did not affect secondary sphere for-
mation (Fig. 6e). The specific inhibitory effect of NF-κB activation 
inhibitors on primary sphere cells’ ability to form secondary spheres 
also  correlated  with  a  functional  inhibition  of  tumour-initiation 
(measured by tumour volume; Fig. 6f). Administration of the MET 
receptor inhibitor PHA and the NF-κB activation inhibitor celastrol 
to primary sphere-forming cells of DU-145 and PC-82 OT-tumours 
also  inhibited  their  ability  for  in  vitro  secondary  sphere  forma-
tion (Fig. 6g) and in vivo tumour-initiation (Fig. 6h). Importantly, 
administration of these inhibitors to the prospectively purified pri-
mary sphere-forming TRA-1-60-positive cells of the various human 
prostate tumours mentioned above similarly inhibited secondary 
sphere-formation  in  cultures  and  tumour-initiation  in  animals. 
Finally, we confirmed that the activation inhibitor of NF-κB, 481407   
induced apoptosis as determined by the accumulation of cleaved   
caspase  and  by  poly  ADP  ribose  polymerase  (PARP)  cleavage   
(Fig. 6i). Under these conditions, neither the activation of AKT 
kinase  (measured  as  phospho-AKT  levels)  nor  its  downstream 
signalling  (phosphorylation  of  S6  ribosomal  protein  (S6RP)),  is 
affected, demonstrating a specificity of this drug for inducing apop-
tosis  in  NF-κB  activated  stem-like  TICs.  In  contrast,  LY294002 
and rapamycin inhibited the phosphorylation of S6RP as expected, 
without inducing apoptosis as determined by the lack of accumula-
tion of cleaved caspase and PARP cleavage products.
Discussion
The precise cell type(s) responsible for development of human pros-
tate  cancer  and  the  mechanism(s)  behind  the  resistance  against 
traditional  prostate  cancer  therapies  in  patients  remain  elusive. 
This study identifies a subset of AR-/PSA-negative human prostate 
tumour cells, which have stem-like cell characteristics and are effi-
cient TICs. On the other hand, these stem-like TICs express MET, 
CK5 and SOX9, which characterize them as being more stem-like 
basal cells than differentiated luminal cells in the prostate. However, 
little or no expression of Nkx3.1, ZO-1, CK18 and p63 also identifies 
them as a largely undifferentiated and nonpolarized subset of basal 
cells and compares them to adult prostate stem cells localized in the 
Low
S/TFE set
Moderate
S/TFE set
0
0
27
27
0 25
10
High
S/TFE set
P-values (enrichment)
GO:0048468
Cell development
GO:0006915
GO:0030154
GO:0008219
GO:0050794
Regulation of cellular process
1.00E–08 1.00E–06 1.00E–04 1 2 3 4 5 6 7
Cell differentiation
Cell death
Apoptosis
Fold enrichment
IGFBP7 GSTA5
_id_430615 _id_6980112
VCX
tcag7.23
ANXA1
XM_932975
XM_938755
XM_927140
CSNK2A2
XM_934365
XM_931572
TPM3
NM_138687
PTPLAD2
XM_929199
_id_4260156
_id_6110241
_id_840189
_id_4390136
LOC387763
_id_4280189
STC1
TIMP2
XM_928885
ETS1
APOBEC3F
CEBPB
CXCR4
XM_930560
CLIP3
C9orf41
USP49
XM_934651
XM_934113
XM_926458
NM_001029862
LOC440704
ALPP
HSD17B7 _id_1980521
PSENEN
PRRX1
PIM1
NM_194295
SIGLEC12
DPYSL3
MCM8
FAT
SGK1
RND1
FKBP1A
XM_941980
IL18
TCF4
NRBP1
TAF10
XM_944019
XM_371152
TGIF1
–8 –4 0
–8 –4 0
–8 8 –4 4 0
XM_497272
SPARCL1
XM_930995
_id_3180709
_id_5690020
_id_6110632
_id_4150706
CGB8
NRAP
XM_933516
CGB5
–20 –16 –12 –8 –4 0
XM_938419
_id_5080673
XM_937384
LGALS1
LOC554223
IFIH1
PMP22
NFKBIA
ZEB2
BU742360
CHIC2
FILIP1L
TSHZ1
TPM2
SOD2
APOE
CRYAB
Figure 5 | Global mRNA expression in marker-positive human prostate tumour cells. (a) Venn-diagram of genes differentially expressed in 
prospectively isolated CWR22 oT-tumour cells with low (expressing EpCAm, CD44 or α2-integrin), moderate (expressing TRA-1-60, CD151 or CD166) 
and high (triple-marker-positives) sphere/tumour-forming efficiencies (S/TFE). Gene expression data in β4-integrin-positive (no sphere-forming) cells 
and the total tumour cells were used as baseline expression control. (b) Fold enrichment of gene ontology based functional categories in all the S/TFE 
data sets. (c–f) Catalogue of top differentially expressed genes: (c) shared among all the above three data sets, (d) shared between moderate and high 
S/TFE data sets, (e) expressed specifically in moderate S/TFE data set and (f) expressed specifically in high S/TFE data set. ARTICLE
0
NATuRE CommuNICATIoNS | DoI: 10.1038/ncomms1159
NATuRE CommuNICATIoNS | 2:162 | DoI: 10.1038/ncomms1159 | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
basal epithelial cell compartment of the normal gland27,33. The lack 
of p63 expression in the basal cell-like sphere cells is also consistent 
with previous data on the presence of a p63-negative, stem-like sub-
set of basal cells in the prostate gland34 and the androgen-dependent 
regeneration of hormone refractory regressed p63 − / −  prostate35.   
A key function of basal cells with CK5 + /p63– phenotype was found 
in prostate cancer development5. Enhanced expression of Ki67 (a 
proliferating  cell  marker)  and  weak  expression  of  differentiated 
epithelial tumour cell (including prostate) marker, α-B-crystallin, 
in the sphere cells (Fig. 1h) further defines them as stem-like pro-
liferating cancer cells. However, expression of at least one luminal 
cell-specific marker, cytokeratin-8 (CK8) in these stem-like TICs 
characterizes them as a distinct subset of basal cells with a cytokeratin 
  expression pattern intermediate between CK5-positive basal cells 
and CK18-positive luminal cells. Similarly, intermediate cell types 
have been implicated in the growth of prostate or invasive prostate   
carcinoma5,36,37, and these cell types were also shown to express high 
levels of MET receptor38.
Although MET is expressed in prostate basal epithelial cells39 
and stem cells associated with cancers40, overexpression of human 
MET was shown to have an important role in cellular transforma-
tion, and to indicate poor prognoses of a variety of epithelial can-
cers in patients. The inverse relationship between the expression 
levels of MET receptor and AR in sphere-forming TICs is consist-
ent with previous reports on cellular transformation and androgen-
  independent prostate cancer growth41,42. Sox9 is known to have a 
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role in maintaining the committed stem cell compartment by regu-
lating AR levels and cell proliferation rates43. Recently, the induc-
ible lineage-marking experiments revealed that a rare population of 
castration resistant Nkx3.1 positive luminal cells (although negative 
for expression of basal cell markers) induced prostate cancer in a 
mouse model of conditional Pten tumour suppressor gene dele-
tion14. However, in a comparable activated AKT signalling back-
ground, prospectively isolated mouse prostate basal cells induced 
tumours  more  efficiently  than  their  luminal  cell  counterparts13.   
Our data on human prostate tumours suggests that this subset of 
undifferentiated  stem-like  basal  cells  may  represent  at  least  one 
subtype of cancer stem-like cells. It is possible that there may be 
more than a single stem-like TIC type, and that multiple stem-like 
cell characteristics reflect differential activation of various onco-
genic  signalling  pathways  in  the  context  of  complex  cancer  cell 
paradigms7–10. Thus, even from the point of view of therapy devel-
opment, it becomes important to precisely discriminate the cell type 
of origin in any given tumour. A very recent report corroborates 
our data, suggesting that in a transgenically manipulated oncogene-
induced tumour paradigm, only basal, and not luminal, cells isolated 
from radical proctectomy patient specimens are capable of tumour 
induction on xenotransplantation44. Together, our data unveils a 
largely undifferentiated subtype of human prostate TICs with the   
AR − /PSA − /NKX3.1 − /SOX9 + /p63 − /CK5 + /CK8 + /CK18 −  phenotype.
Interestingly,  in  comparison  with  the  total  tumour  cells,  the 
TICs  showed  no  substantial  differences  in  expression  levels  of 
cancer-associated canonical receptor tyrosine kinases and/or their 
associated/downstream  signalling  components  (Fig.  6a;  Supple-
mentary Fig. S1a,b,d). The specific activation of PKCα/NF-κB sig-
nalling in stem-like human prostate TICs is consistent with the pre-
vious findings that phosphorylated forms of classical PKCs (such 
as PKCα) and the downstream novel PKCs mediate activation of 
NF-κB  signalling45.  These  conditions  may  have  affected  normal 
NF-κB homeostasis46 in the stem-like TICs to result in constitu-
tive activation of NF-κB, which in turn regulates a battery of genes 
associated with apoptosis and tumourigenesis, as deduced from the 
global gene expression data. The genomic expression data as well 
as subsequent biochemical data-driven delineation of NF-κB sig-
nalling axis involving the IL-6/MCL-1 in the functional stem-like 
TICs was consistent with other relevant findings such as IL-6 (a 
NF-κB target) regulation of MCL-1 expression and mediation of 
cell survival responses by blocking apoptosis during late stage pros-
tate carcinoma47,48, or activation of NF-κB via a positive feedback 
loop to maintain neoplastic transformation in a cell culture model 
system49.
Moreover, involvement of NF-κB-dependent cell survival signal-
ling was also implicated in downregulation of AR expression by the 
activated PKC pathways50 and there was a mutual transcriptional 
interference between the expression of NF-κB p65 and AR51. Our 
results also support the contention that the activated PKCα/NF-κB 
pathway could have resulted in the observed lack of AR accumu-
lation in the stem-like human prostate TICs. Although previous 
studies suggest a functional role of NF-κB signalling in different 
clonally-derived in vitro cultured tumour cells (for example, both in 
CD133-positive24 and -negative23 human prostate tumour cell cul-
tures), epigenetically transformed cell lines49 and in mutant-KRAS 
animal tumour models52, our data reveals for the first time a specifi-
cally increased and functional NF-κB signalling in the prospectively 
purified naïve stem-like human prostate TICs. A strong correlation 
was also found between positive NF-κB nuclear staining in patients’ 
radical prostatectomy specimens with positive margin prostate can-
cer and a several-fold increase in their risk for biochemical recur-
rence of this disease53. Furthermore, our inhibitor screening data 
is corroborated by recent hierarchical clustering of multi-marker 
immunohistochemical analyses on the prognostic significance of 
human prostate cancer54, which revealed that nuclear NF-κB, but 
not  phospho-AKT,  was  associated  with  biochemical  recurrence 
of this disease in radical prostatectomy patients. Thus, the PKC/
NFKBIA/NF-κB-dependent  anti-apoptotic  signalling  deciphered, 
here, may represent at least one functional pathway crucial in the 
maintenance of a definite marker-expressing, therapeutically resist-
ant and prognostically relevant stem-like TICs in human prostate 
cancers. Finally, our screening design to test for candidate small 
molecule inhibitors that target TICs in a cell type specific manner 
may represent an interesting approach for other human prostate 
tumour models and tumours of other organ systems.
Methods
Institutional protocols. All animal experiments and human patient specimen-
procurement were performed in accordance with protocols approved by our 
Institutional Animal Care and Use Committee and Institutional Review Board 
following National Institutes of Health guidelines for animal welfare and human 
subject research.
Prostate tumours and tumour cell-derived spheres. Prostate tumour tissues 
were minced with Miltex stainless steel disposable safety scalpels in serum-free me-
dium (serum-free insulin rich N2 medium55 or human embryonic stem cell (HES) 
medium56), supplemented with 2% B-27 supplement without vitamin A (Invitro-
gen), 20 ng ml − 1 FGF2 (R&D Systems) and 20 ng ml − 1 EGF (R&D Systems). Tissue 
was digested with 0.5 mg ml − 1 collagenase Type 1A (Sigma) and 100 U ml − 1 RNase-
free DNase (Promega) to reduce cell clumping during tissue dissociation for 90 min 
at 37 °C with constant agitation. Dissociated tissue was passed through 100 µm 
cell strainer filter (BD Falcon). The resulting cells were pelleted at 800 g using the 
Figure 6 | NF-κB-signalling in stem-like human prostate TICs. Western blots of whole cell extracts of the parent tumour, spheres and the sphere tumour 
analyzing (a) various signalling pathway components, with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) representing loading control. (b) 
Nuclear localization of NF-κB in stem-like sphere-forming cells. Immunofluorescence (scale bar, 100 µm) or immunohistochemistry (scale bar, 50 µm) of 
acetylated (K310) NF-κB visualized in the nucleus and counterstained by DAPI (IF) or hematoxylin (IHC). (c) Comparative immuno-histochemical analysis 
of mCL-1 expression in primary spheres versus the parent tumour, sphere tumour and human patient primary tumour. Scale bar, 100 µm. (d) Dose-
dependent effects of small molecule inhibitors on secondary sphere formation. Inhibitors were administered to primary sphere-forming total tumour cells. 
Red, PHA (PHA 665752); brown, parthenolide; black, 481407; green, celastrol. (e) Preliminary screening to test effect of inhibitors of different signalling 
pathways on secondary sphere-formation in vitro. PHA (10 µm), parthenolide (10 µm), 481407(5 µm), celastrol (2 µm), BAY (BAY11-7082, 10 µm), 
staurosporine (0.05 µm), mG132 (0.5 µm), LY (LY294002, 10 µm)  +  rapamycin (20 nm), cyclopamine (2 µm) or DAPT (10 µm) were administered, 
wherein the control represents dimethylsulphoxide (DmSo)-treated set. (f) Primary sphere-forming tumour cells were treated with the inhibitors of mET 
(PHA: 20  µm), activated NF-κB signalling, (parthenolide: 20 µm; 481407: 20 µm; celastrol: 3 µm), PI3 kinase signalling (LY 294002: 15 µm) + mToR 
signalling (rapamycin: 40 nm) or Notch signalling (DAPT: 20 µm) were xeno-transplanted subcutaneously. Tumour size was determined by tumour 
volume at the 5-week end point. (g, h) Effects of these signalling inhibitors on secondary sphere formation (g) and tumour-initiation (h) across multiple 
human prostate tumour xenograft models. Same number of total tumour cells from human prostate Du-145 SC-(blue)/ PC-82 oT-(red) tumours or 
prospectively purified TRA-1-60-positive cells from the CWR22 oT-(green)/Du-145 SC-(pink) tumours were used. Tumour size was determined as above. 
(i) Immunoblot analyses of cleared caspase (Cl-caspase) and PARP cleavage in the primary spheres following administration of NF-κB and AKT/mToR 
signalling inhibitors. Whole cell extracts prepared 6 h-post drug administration were analysed by western blotting. Control represents DmSo-treated set, 
whereas the total AKT and total S6RP levels served as loading controls. mean ± s.d., n≥4.ARTICLE
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Eppendorf centrifuge 5810, and the pellet was treated with 1× conc of BD Pharm 
Lyse lysing buffer (BD BioSciences) for 1 min to deplete erythrocytes followed by 
neutralization in phosphate buffered saline. Live cell numbers were determined as 
a function of trypan blue exclusion. The cells were pelleted as above, washed and 
plated for sphere-formation with N2 medium, while similar results were obtained 
with the human embryonic stem cell medium at a cell density of 40–80×106 cells 
per 15 ml medium (unless stated otherwise) in nonadherent 10-cm dishes (Costar). 
For determining sphere-forming efficiency, dissociated total tumour cells or the 
primary sphere-derived cells (following Acutase treatment and trituration) were 
plated in 6–12 well nonadherent plates at the desired cell densities. The medium 
was changed daily along with growth factor supplementation, and the spheres were 
collected at the specified time points following gravity-based sedimentation and/or 
low-speed centrifugation to remove any remaining single cells. Spheres were then 
washed once with phosphate buffer saline, followed by gentle resuspension in cell 
detachment solution (Accutase/Accumax, Innovative Cell Technology; with the 
aid of a pipette tip) and constant trituration (twice for every 3–5 min) for at least 
20 min to obtain single cells. The dissociated single cells of the primary spheres 
were washed at least three times with the N2 medium and then plated for sequential 
sphere-formation for an additional 3–6 days or transplanted immediately into mice 
at OT or SC sites for tumour-initiation assays.
Western blotting. Immunoblotting was performed with whole cell lysates as pre-
viously described,57 with the following modifications. The cell lysates (200 µg per 
well) were separated in 4–12% Bis–Tris NuPAGE gel (Invitrogen) using the i-Blot 
gel transfer system essentially using the reagents and the materials supplied by the 
manufacturer (Invitrogen). All the washings were for 15 min with the phosphate 
buffer saline containing 0.1% Tween-20 (Fisher Scientific); the last wash before 
chemical detection of the western reaction was without Tween-20. Primary anti-
body binding was visualized by chemiluminescence derived from the Super Signal 
West Pico substrate (Pierce) with the HRP-secondary antibody conjugate (Pierce). 
Chemiluminescence was captured on Kodak Biomax MR Film (Kodak).
Prospective purification by FACS. Dissociated tumour or sphere cells were sieved 
through nylon cell strainers (70 µm; BD Falcon) and pelleted in aliquots of  > 106 
cells for BSA blocking in FACS buffer, followed by incubation with various conju-
gated primary antibodies at the manufacturers’ suggested and/or pre-optimized con-
centrations for 90 min at 4 °C in the dark with the same buffer in a final volume of 
100–500 µl. The cell samples were then pelleted, the supernatant aspirated and then 
washed twice with FACS buffer without antibodies, and maintained in the dark on 
ice until subjected to FACS (for a maximum of 1 h). Flow cytometric data acquisition 
and sorting were carried out using a stream-in-air FACS Vantage DiVa cell sorter 
(BD Biosciences) equipped with three lasers (488, 633, 360 nm) and optics for seven-
color data acquisition. DiVa software version 4.1.2 was used to acquire and sort 
cells positive for Alexa 488 + , Alexa 647 + , APC + , FITC +  and PE + . Instrument 
performance was verified before acquisition using standard fluorescent microparti-
cles (SPHERO Rainbow Fluorescent Particles, RFP 30-5A, Spherotech). Fluorescent 
detector voltages were set so that the unstained cells were on scale, and compensa-
tion was calculated manually in the DiVa software using single-stained controls. 
Data analysis was performed using FlowJo software version 8.7.3 (Tree Star). Greater 
than 30,000 events were collected and gated to include live cells (forward scatter 
versus side scatter) and exclude doublets (forward scatter area versus forward scat-
ter height). Singlet-gated unstained cells were used to draw gates to identify Alexa 
488 + , Alexa 647 + , APC + , FITC +  and PE +  single-positive (Supplementary Figs S2 
and S3a–c) or double-positive (Supplementary Fig. S3d–f) populations depending 
on the stain used. Unless stated otherwise, for sorting and analysis of these triple-
marker-positive (Alexa 488 conjugated TRA-1-60 + /PE conjugated CD151 + /Alexa 
647 conjugated CD166 + ) cells, we selected the brightly triple-marker-positive cell 
populations (high expressors; Compare Supplementary Fig. S4a,b) and excluded 
cells with low expression (total expressors; Supplementary Fig. S4a–c) of the three 
markers. Strategies to gate for triple-negatives are also depicted (Supplementary Fig. 
S4d). Percent sphere-formation was routinely greater in the high expressors than 
in the low expressors of these triple-markers. By using alternative fluorochrome(s) 
conjugated to the same primary antibodies (such as Alexa 647 conjugated anti-
TRA-1-60 or anti-CD-151 antibodies and PE conjugated anti-CD166 antibody) the 
specificity of antigen expression on the tumour cells was verified.
Microarray. Total RNA was isolated from freshly snap-frozen tumour cells, 
spheres and the prospectively purified cells using TRIzol and suggested protocol 
(Invitrogen). All the samples of a given set were processed in parallel for total RNA 
extraction to avoid batch variations. Total RNA samples were processed by the SKI 
Genomics Core Facility for mRNA and miRNA analysis using standard proto-
cols. Gene expression analysis was performed using the Illumina Human Ref6V2 
bead chip arrays. Analysis of miRNA expression was performed using the Agilent 
miRNA microarrays (Human_miRNAV1, Agilent). Scanned images were proc-
essed with the Illumina bead studio program to define levels of gene expression. 
These raw data were further processed using the Bioconductor Lumi package to 
normalize (quantile) and log-transform the data. For miRNA analysis, scanned im-
ages were processed with the Agilent feature extraction program, which provided 
raw signal values for each miRNA (Gene signals). The data were normalized using 
Variance Stabilization Normalization from the Bioconductor VSN package and 
log-transformed. Data computation for both mRNA and miRNA are as follows: to 
compute differentially expressed ‘genes,’ the Bioconductor LIMMA packages was 
used for a corrected t-test using an empirical Bayes method to compute variance 
correction and P values. To adjust for multiple testing, the False Discovery Rate 
method was used. Fold changes were converted to the signed real space conven-
tion; fold changes less than zero are the minus of the reciprocals; that is,  − 2 is 
really 1/2. Average signal levels are the averages of the log signal transformed back 
into real space. Genes were annotated for their associated biological processes 
and molecular functions by Gene Ontology project (http://www.geneontology.
org/index.shtml). Comprehensive functional annotation of the gene sets was car-
ried out with the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) 2008 program (http://david.abcc.ncifcrf.gov/). The miRNA targets 
and expression were determined using publicly available databases (http://www.
targetscan.org/ and/or http://www.microrna.org/microrna/home.do). The miRNA 
function in gene and pathway regulation was obtained using ARGONAUTE 2- 
database (http://www.ma.uni-heidelberg.de/apps/zmf/mirwalk/). Both the RNA 
and miRNA expression data sets are deposited in GEO (http://www.ncbi.nlm.nih.
gov/geo/) with accession numbers GSE25690 and GSE25691, respectively.
Screening of stem-like TICs with small molecule inhibitors. Inhibitors of vari-
ous signalling pathways, namely, Met receptor kinase (PHA 665752 (PHA), Tocris 
BioScience), NF-κB signalling (481407 compound (Calbiochem); parthenolide 
(TocrisBioScience), celastrol (TocrisBioScience), BAY11-7082 (Calbiochem)), PKC 
signalling (Staurosporine (Calbiochem)), proteasomes (MG132 (Calbiochem)), 
MAP kinase (U0126 (Promega)), PI3 Kinase (LY 294002 (Calbiochem)), mTOR 
(Rapamycin (Sigma)), Hedgehog signalling (Cyclopamine (Sigma)) or Notch 
signalling (DAPT: N-[N-(3,5-difluorophenacetyl-l-alanyl)]-S-phenylglycine 
t-butyl ester (Sigma)), were administered for 16 h to total tumour cells about 60 h 
post-initiation of primary spheres. The primary spheres were collected, washed 
twice with the same growth medium depleted of the inhibitors and finally once 
with phosphate-buffered saline. The spheres were then dissociated into single cells 
as described above. Dimethylsulphoxide-treated sample served as control for the 
inhibitor-treated ones. For testing the effect of various small molecule inhibitors 
on primary sphere-formation, we used at least 100,000 total tumour cells isolated 
from different human prostate tumour xenografts as described. To follow the 
subsequent effects of the same inhibitors on secondary sphere-formation, we used 
at least 5,000, 25,000 and 10,000 primary sphere cells derived from human prostate 
CWR22 OT-tumours, parent DU-145 SC-/PC-82 OT-tumours and the prospec-
tively purified TRA-1-60-positive cell-derived DU-145 SC- /PC-82 OT-tumours, 
respectively. To investigate the tumour-initiation ability following the above inhibi-
tor treatments, 2500–5000 primary sphere cells were transplanted as indicated.
Additional experimental details are described in the Supplementary Information. 
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